|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||16.01 - 16.93|
|52 Week Range||8.13 - 25.25|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||159.60|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||24.46|
BOULDER, CO, July 16, 2019 /PRNewswire/ - Charlotte's Web Holdings, Inc. ("Charlotte's Web" or the "Company") (TSX:CWEB, OTCQX:CWBHF), the market leader in hemp CBD extract products, is pleased to announce that Tony True has joined the Company in the newly formed role of Chief Customer Officer. Mr. True comes to Charlotte's Web from Pharmavite LLC, one of the largest U.S. manufacturers of high-quality vitamins, minerals, and other dietary supplements, where he served as Executive Vice President, Sales. As Chief Customer Officer for Charlotte's Web, he will lead the Company's sales strategy and forecasting, customer development and relationships, and retail execution.
Among the major cannabis plays, Canada's Aurora Cannabis (NYSE:ACB) has mostly gone its own way. Rivals Canopy Growth (NYSE:CGC) and Cronos (NASDAQ:CRON) have sold billions of dollars' worth of stock for cash to fund their growth. Aurora, instead, has used ACB stock to buy smaller companies. It has issued over 1 billion shares of Aurora Cannabis stock in the last few years.Source: Aurora Cannabis The good news with that strategy is that Aurora may have the broadest reach of any cannabis play. Per a recent investor presentation, Aurora is active in 24 countries across five continents. This is true from a product standpoint as well: Aurora offers not just cannabis flower but softgels, edibles, and CBD (cannbidiol) products.It's an intriguing strategy -- one with huge risk and huge reward, as I wrote earlier this year. The steady issuance of ACB stock has diluted shareholders. This means Aurora needs huge profits in order to post reasonable earnings per share (EPS). The company is expected to generate about U.S. $552 million in revenue next year; it would need over U.S. $1 billion in earnings to get its EPS over $1.InvestorPlace - Stock Market News, Stock Advice & Trading TipsOf course, that type of growth is more likely for a diversified operator. But to achieve that growth, Aurora stock needs help in one key area. It needs marijuana legalization to move beyond Canada and a few smaller markets -- and it needs that to happen relatively quickly. The Market Risk to ACB StockIt would seem like producers have several markets in which to sell cannabis as possession of marijuana is legalized or decriminalized in areas around the world.But production is a different matter. Even in the Netherlands, which has been a destination for marijuana users for some time, growing marijuana is illegal. At the moment, only Canada and Uruguay offer truly legal opportunities for companies like Aurora. * 7 F-Rated Stocks to Sell for Summer The problem is that those two markets aren't enough. There are hundreds of companies in Canada trying to get a piece of what Aurora itself has estimated at just a CAD $12 billion market. The medical market is pegged at CAD $3 billion, and the consumer market at CAD $9 billion.Even adding in medical opportunities in countries like Germany, the problem holds. There are too many companies, too much supply, chasing too few buyers. As we have seen in U.S. markets like Oregon and Colorado, that leads to plunging prices, thin margins, and likely a lower ACB stock price. Markets Really Matter to Aurora Cannabis StockFor most marijuana plays, Canada alone isn't enough. But smaller plays like Hexo (NYSEAMERICAN:HEXO) can manage better in a single market. So can a company like Charlotte's Web (OTCMKTS:CWBHF), whose CBD focus allows it to drive sales in the U.S. and elsewhere.In contrast, Aurora's strategy is based on becoming a major worldwide player. That's why it continues to build its production capacity, rivaling Canopy for the biggest in the world. That is also why it has acquired so many businesses in far-flung destinations like Uruguay, where it made a $290 million acquisition last year.In many cases, Aurora's initial aims are to penetrate the medical side of the market -- and it appears to be building leadership in that category (their competitor, Canopy, has seen its medical sales decline of late).But the bull case for Aurora, as it heads toward a whopping 1 million kilos of capacity, requires the demand match that production. That means recreational legalization on the producer side -- not just decriminalization. Is That a Worry for ACB?It looks like a risk from here. Unlike Canopy, who has a deal to enter the U.S. market, Aurora has no U.S. presence yet. Its growth will rely at least in part on legalization in Europe, Latin America, and the Oceania region.The news in those areas is mixed. Movement in Europe has been slow in part because the continent lacks ballot initiatives. The impact of that absence can be seen in the U.S., where legalization has moved by direct democracy, with politicians reluctant to embrace legalization beyond medicinal use.Spain is a candidate for legalization, however, and Belgium may head in the same direction. Still, European movement overall seems like it will be slow.In Latin America, Mexico may well see legalization after a recent Supreme Court decision. (Aurora has a presence in that market.) Outside of that country, however, there are reasons for caution. Brazil, led by conservative President Jair Bolsonaro, almost certainly will not pass legalization. Smaller countries have moved toward decriminalization -- but not outright legalization of production, particularly in scale.New Zealand has a referendum on the way in 2020 that could open that market. Progress in Australia has stalled out, however.Over time, marijuana will likely gain acceptance. But for Aurora Cannabis stock, the definition of "over time" is exceedingly important.It still trades at about 14.4x fiscal 2020 sales forecast of $552 million. Growth from there may depend on how many new markets open for the company, particularly on the recreational side. If the pace of opening disappoints, ACB likely will too. If marijuana legalization gains steam worldwide, however, there isn't a company better-positioned. Investors should place their bets accordingly.As of this writing, Vince Martin has no positions in any securities mentioned. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 F-Rated Stocks to Sell for Summer * 7 Stocks to Buy for the Same Price as Beyond Meat * 7 Penny Marijuana Stocks That Are NOT Cheap Stocks The post Global Legalization Will Determine the Fate of Aurora Stock appeared first on InvestorPlace.
Charlotte's Web Holdings (CWBHF) has been one of the few cannabis companies in the world that has been not only able to consistently grow revenue, but do so at a profit.The company competes in the hemp-based cannabidiol (CBD) extracts and products segment of the cannabis market.Up until about a month ago, my thesis was that the market would reward cannabis companies that generated the most revenue. While that remains true, it's becoming evident to me that cannabis companies that are able to increase revenue at a significant pace while lowering costs and generating positive earnings, are going to start to get the strongest bid from the market.This is one of the reasons I see Aurora Cannabis starting to become more favorable to the market than Canopy Growth, which has continued to grow revenue, but at a huge loss; in its latest quarter it lost over $74 million.Charlotte's Web has already started to produce earnings, and it's likely that will continue for the foreseeable future.Latest quarterIn its latest earnings report the company took a tumble, primarily I think from the market in general become more risk averse, and second, its earnings per share missing slightly.Revenue in the reporting period was $21.7 million, in-line with expectations, while EPS was $0.02, missing by $0.01.Revenue was up 66 percent year-over-year, and gross profit jumped by 53 percent. Where I think some of the negative sentiment came from in its performance itself, was with its earnings before taxes, where it dropped 27 percent. Net income was also down by 26 percent.The company guided for revenue to increase at a pace quicker than costs for the remainder of 2019, meaning it should be able to boost sales at a profit. That suggests the company will continue to maintain positive earnings going forward.In 2019 earnings is expected to reach 33 cents per share, and in 2020 the company guides for earnings per share of 75 cents.A little over 50 percent of revenue in the reporting period came from over 6,000 retail stores, with the remainder primarily coming from its fast-growing e-commerce business.Revenue for 2019 is projected to be around $142.9 million, according to the company, and in 2020 that's expected to more than double to over $300 million.One concern I do have concerning revenue is the guidance for 2019, which is projected to be in a range of $120 million and $170 million. The problem to me is there should be such a wide number between the revenue floor and ceiling. It makes me think the company sees something potentially on the down side that could disrupt sales flow. It's possible it could be the timing of the harvests and the amount of time it has to sell through during 2019.Planted acreage increasingTo get an idea of how quickly Charlotte’s Web Holdings has been increasing the amount of acreage it plants, in 2017 it planted only 70 acres of hemp, which produced a harvest of 63,000 pounds. It followed that in 2018 with a total of 300 acres planted, producing a harvest of 675,000 pounds.Earlier in the year the company stated it was going to boost its planted acreage to 700 acres, but in mid-June upwardly adjusted that to 862 acres. Assuming a similar yield per acre, that will easily more than double its output in 2019.Investors should be able to count on well over 1 million pounds of hemp to be grown this year.Also of interest, is of the 862 acres being planted, about 53 percent of them are certified organic. Management has said it plans on increasing the percentage of organically certified hemp in the years ahead. That would boost margins and earnings.ConclusionThe recent sell-off of the stock as a result of the uncertainty surround the trade wars and the earnings before taxes and net income both dropping. This pushed the share price down to under $12.00 per share.But even now the company is trading at under $15.00 per share, and with the projected acreage and revenue outlook, a couple of analysts have the company almost doubling, or more than doubling its share price from these levels. I think they're close to the mark.Not long ago, Charlotte's Web started shipping product to three major retail brands in the U.S., and that should boost its own brand awareness and popularity among customers.With CBD sales expected to explode over the next three years, I'm not aware of any company better positioned than Charlotte's Web to take advantage of it.Investors need to take a quick look at this stock before it starts to take off once again. This is a very good entry point if you believe in the narrative surrounding the future performance of the company.To read more on the nitty gritty of what’s going on in the rising cannabis industry, click here.Read more on Charlotte's Web: While Risky, Cannabis Stock Charlotte’s Web Is Too Cheap to Ignore More recent articles from Smarter Analyst: * Organigram (OGI) Reported a Strong Quarter, But Don’t Buy the Stock Just Yet * More Gains Ahead for Cannabis Stock Curaleaf * Last Minute Thought: Buy or Sell Netflix (NFLX) Stock Before Q2’19 Earnings? * Is It Finally Time to Go Long NIO Stock? This Analyst Remains Sidelined
Editor's note: This column is part of our Best Stocks for 2019 contest. Jason Moser's pick for the contest is Teladoc Health (NYSE:TDOC).Teladoc looked like it was going to end the quarter in fourth or even fifth place. But after a rally that started last Wednesday, TDOC stock slid past Adobe (NASDAQ:ADBE), Amazon (NASDAQ:AMZN) and Charlotte's Web (OTCMKTS:CWBHF) for a second-place finish.InvestorPlace - Stock Market News, Stock Advice & Trading TipsSo how does TDOC look going forward? TDOC's First Quarter EarningsTeladoc's first quarter was a good one. Revenue of $128.6 million marked growth of 43% (23% organic) and total U.S. paid members are now at 26.7 million along with 10.2 million visit fee-only users. Total visits of 1,063,000 represented 29% organic growth.It's also worth noting that this represented the first quarter where the business crossed 1 million doctor's visits, and that was actually in spite of a weaker flu season. International visits grew from basically nothing a year ago to 282,000 this quarter.Gross margin was 65.3% versus 70% a year ago and as we've seen in previous quarters this investment in behavioral along with a more comprehensive offering. TDOC's balance sheet remains in good shape considering the deals the company has made recently with $479 million in cash and equivalents and $450 million debt. It's also worth noting that debt is in convertible notes that don't even come due until 2022 and 2025. Looking Ahead for TDOCThe business is still unprofitable but what else is new? Profitability will come in time and management reiterates that the company will be cash flow positive for the first time in 2019 so we'll hold them to that target. * 7 Restaurant Stocks to Put on Your Plate The CVS and Aetna relationships have never been stronger and we should expect some additional news regarding Teladoc and Aetna at some point in the near future as well.CEO Jason Gorevic likes this business because there are so many levers for growth. I tend to agree; healthcare is a phenomenally large global market opportunity.One final note, the CFO search is over as Mala Murthy has joined the Teladoc team. A seasoned vet, Murthy comes to the company from American Express so it's encouraging to see the team in a good place going forward.As of this writing, Jason Moser, a senior analyst with The Motley Fool, held shares of TDOC. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 F-Rated Stocks to Sell for Summer * 7 Stocks to Buy for the Same Price as Beyond Meat * 7 Penny Marijuana Stocks That Are NOT Cheap Stocks The post Best Stocks for 2019: Teladoc Stock Is Here to Stay appeared first on InvestorPlace.
Editor's note: This article is part of InvestorPlace.com's Best Stocks for 2019 contest. Matt McCall's pick for the contest is Charlotte's Web Holdings Inc(OTCMKTS:CWBHF).I've been recommending marijuana investments since 2014. That's five years now. Many of my early recommendations have soared hundreds, even thousands of percent.InvestorPlace - Stock Market News, Stock Advice & Trading TipsI've gotten to know many of the most important players in the industry. I've also personally invested in private marijuana deals that have produced some stunning success.A colleague of mine even refers to me as "The Original Marijuana Stock Bull."I'm flattered to be considered one of the earliest and most plugged-in marijuana investors. But at no time in the past five years have I seen the level of marketing related to marijuana investments that we're seeing now. It seems that everyone is starting to call themselves a marijuana expert. Guys who were defense industry analysts a month ago are now pounding the table on marijuana.I guess it's better late than never?Interest in sectors and asset classes ebbs and flows, and because the marijuana industry has been flying so high in recent months, we were overdue for a short-term correction. * 6 Worst S&P 500 Stocks of 2019 (So Far) We're seeing that now. But don't make the same mistake a lot of people are making. Don't sell your holdings because some idiot tells you "the marijuana bubble has popped."Instead, focus on the long-term picture. And in this case, the long-term picture of the marijuana industry has never been more promising.That brings me to my pick in the Best Stocks for 2019 contest.Charlotte's Web (OTCMKTS:CWBHF) isn't your typical marijuana company. It focuses on a niche sector within the larger industry -cannabidiol, also known as CBD. According to Brightfield Group, the hemp-derived CBD market is poised to increase from $591 million in 2018 to $22 billion by 2022. That is nearly 40x growth in four years!Charlotte's Web is the early leader in this booming, up-and-coming industry. It produces and distributes CBD wellness products, including everything from tinctures to topicals to capsules, both online and in stores. And as a result, it has become the world's leading CBD brand by market share.The company has been a pioneer in the industry since being founded in 2013. Its brand became well known after a CNN documentary aired based on the life of a little girl named Charlotte Figi. Charlotte suffered from up to 300 grand mal seizures per week, but she found treatment -- and almost a cure -- in cannabis oil. The brothers who manufactured the strain went on to found Charlotte's Web.If you're interested in reading more about Charlotte's story, check out my initial recommendation here. Nothing Can Stop Charlotte's Growth TrajectoryThrough the first quarter of 2019, Charlotte's Web rallied an unbelievable 80%. It continued to a high of $25.25 on April 4 -- a gain of 127%! -- before getting caught up in the broad volatility we talked about earlier.To add insult to injury, the company also got hit by a few other negative headwinds. Still, neither impacts its long-term potential one iota.The first was insider selling. While it's not something we ever want to see, it can happen for understandable and legitimate reasons, especially after a company goes public. Early investors want to lock in profits as a smart financial decision that has nothing to do with their belief in the business.The second news event was the FDA's hearing on possible regulations for the exploding CBD industry. I'll be honest. I am not usually a fan of regulations. But in this case, more government oversight will benefit both the industry -- which includes Charlotte's Web -- and consumers alike. There are too many bad players in the CBD space that sell junk. Regulations should eliminate the bad players and allow best-in-breed companies to gain more market share. Charlotte's Web already has the largest share of the U.S. CBD market, and that should only grow in the coming years.Back in March, the company's products were available in 3,680 retail locations. Today, that number has exploded to 6,000! Here's how I know that expansion will continue…In April, Charlotte's Web announced a new CEO in a move that tells me a good bit about where this company is headed. And I like what I see. Adrienne Elsner, a former senior executive of the U.S. snacks division of Kellogg, took charge on May 15.The selection of Elsner means that Charlotte's Web will be focused on branding and shelf space in the coming years. Both are very important for the whole industry, and especially for the leading U.S. CBD company. Even though a lot of people who know about CBD have heard of Charlotte's Web, the average American likely still conjures up memories of the great children's book.Branding is a big deal as cannabis goes mainstream. One company has yet to emerge as the McDonald's or Coca-Cola of marijuana. Companies that establish their brands early set themselves up to be huge winners.Charlotte's Web has as good a chance as any to be that first major label. With an experienced consumer brand executive like Elsner at the helm, the odds just get better. Don't Miss Out on CWBHFAs of June 28, Charlotte's Web is up just 32% year-to-date, so it has given up a lot of its early profits. But that's perfectly okay. Not only does this stock have massive potential in the months and years ahead… the weakness is creating a HUGE buying opportunity.Revenue for 2018 came in at $69.5 million, and analysts believe the next three years will bring in revenue of $164 million, $352 million, and $469 million. That would be impressive growth, and we can still buy in at attractive prices.In 2018, Charlotte's Web produced 675,000 pounds of hemp on 300 acres of planted land. The company only had 70 acres of planted land in 2017 and 45 acres in 2016. This year, Charlotte's Web planted 862 acres of hemp -- an increase of 187%. This ability to expand is key to keeping up with demand.There is no question that Charlotte's Web remains my top pick to profit from the CBD market over the long term. The industry leader has a first-mover advantage, and I expect it to continue taking market share as more government regulations force the small, unethical businesses to close their doors for good.Still to come in 2019, I look for the company to announce a major distribution partner --possibly Walmart -- and apply to make the jump to a major U.S. stock exchange. Both are very attainable in the months ahead.In fact, Charlotte's Web has officially made the jump to the Toronto Stock Exchange (TSX) and is now trading under the ticker "CWEB." The upgrade from the Canadian Stock Exchange (CSE) is being news, and it will help attract big institutional money. But the even bigger news will come once the stock makes it onto the New York Stock Exchange (NYSE) or NASDAQ. * 7 F-Rated Stocks to Sell for Summer Based on its current market cap of $578 million, Charlotte's Web is undervalued versus its peers… which adds to the already big upside potential. This is an opportunity we do not want to miss out on.Matthew McCall is the founder and president of Penn Financial Group, an investment advisory firm, as well as the editor of Investment Opportunities and Early Stage Investor. He has dedicated his career to getting investors into the world's biggest, most revolutionary trends BEFORE anyone else. The power of being "first" gave Matt's readers the chance to bank +2,438% in Stamps.com (STMP), +1,523% in Ulta Beauty (ULTA), +1,044% in Tesla (TSLA), +611% in Liquefied Natural Gas Limited (LNGLY), +324% in Bitcoin Services (BTSC), just to name a few. If you're interested in making triple-digit gains from the world's biggest investment trends BEFORE anyone else, click here to learn more about Matt McCall and his investments strategy today. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 F-Rated Stocks to Sell for Summer * 7 Stocks to Buy for the Same Price as Beyond Meat * 7 Penny Marijuana Stocks That Are NOT Cheap Stocks Compare Brokers The post Best Stocks for 2019: Charlotteas Web Is Just Taking a Breather appeared first on InvestorPlace.
Some of those may have gained their wealth through the Evolve Marijuana ETF (TSE:SEED) (OTC: EVVLF), which, in the last year, has delivered the best performance among all cannabis ETFs. Need more cannabis news? Evolve launched SEED on the Toronto Stock Exchange roughly 14 months ago.
After Canopy Growth shares tanked 8% following disappointing earnings, CEO Bruce Linton said he thinks the company will become a leader the CBD market.
Over the course of the last couple of months, Charlotte’s Web (CWBHF) has taken a beating due to U.S Food and Drug Administration concern over CBD products. The stock offers all of the catalysts desired for a cannabis company including national expansion and the uplisting to a major stock exchange suggesting now is the time to really dig into the opportunity with the stock trading around $14.50.Rapid Expansion Charlotte’s Web is the premier company focused solely on the production and distribution of hemp-derived cannabidiol or CBD wellness products. Most other companies in the space are chasing the CBD market as part of a diversified retail plan that includes opening retail locations and cultivation of cannabis.The CBD market is expected to see substantial growth in the next few years. The company quotes a revenue target in the $7 billion range by 2023. Other research firms such as Cowen forecasts the CBD market to reach $16 billion by 2025.Either way, the U.S. CBD market is expected to see rapid expansion over the next five years. In this regard, the market likely didn’t like that Charlotte’s Web only reported slight revenue growth in Q1.The company posted revenues of $21.7 million, only up $0.2 million from the prior quarter. On top of that, management kept guidance for 2019 revenues of $120 to $170 million leaving open the door for only minimal growth.The market wants to see substantial growth despite the stock not trading at a rich valuation anymore.Irrational Sell OffThe stock is down about 40% from the early April high above $25. With 95 million shares outstanding, Charlotte’s Web has a market valuation of just shy of $1.4 billion.The revenue goal based on analyst estimates is in the $350 million for 2020. The stock trades at a very reasonable 3x forward sales estimates for a company with the potential for a premium brand positioning in the health and wellness sector of CBD.A couple of issues hit the stock after reaching that blow off top in early April where the stock nearly doubled in a month. First, the company priced a secondary offering on May 9 for C$140 million worth of shares at C$20 per share. Second, the FDA held a hearing where the federal regulators questioned the long-term safety of CBD with suggestions that food and dietary products might not obtain approval for infusing CBD.Charlotte’s Web is solely focused on CBD so the company has a higher risk that new FDA regulations could impact the business.TakeawayThe key investor takeaway is that Charlotte’s Web is likely to trade volatile like any cannabis related stock due to government regulations. The market appears to have missed the uplisting to the Toronto Stock Exchange at the end of May due to the passing of the 2018 Farm Bill.Now that the froth is out of the stock, investors should look to play Charlotte’s Web on the over played FDA risks and concerns about growth. An uplisting to a major U.S. stock exchange along with a another quarter of substantial growth from expanding with national retailers will have the stock back to old highs before long.To read more on the nitty gritty of what’s going on in the rising cannabis industry, click here. Read more on Charlotte’s Web: * Marijuana Stock Charlotte’s Web Looks Appealing at Current Levels * This Cannabis Stock Is Not Only Friendly to Pets, but Also to Shareholders More recent articles from Smarter Analyst: * Organigram (OGI) Reported a Strong Quarter, But Don’t Buy the Stock Just Yet * More Gains Ahead for Cannabis Stock Curaleaf * Last Minute Thought: Buy or Sell Netflix (NFLX) Stock Before Q2’19 Earnings? * Is It Finally Time to Go Long NIO Stock? This Analyst Remains Sidelined
Charlotte’s Web Holdings (CWBHF)(CWEB) is trading sharply higher today. The stock has been on fire this week and has gained more than 20% so far. Charlotte’s Web saw a selling spree in May, when it lost almost 30% of its market cap. Let’s take a look at what’s driving the stock higher today.
BOULDER, CO , June 19, 2019 /CNW/ - Charlotte's Web Holdings, Inc. ("Charlotte's Web" or the "Company") (TSX:CWEB, OTCQX:CWBHF), the market leader in hemp CBD extract products , today reported final hemp planting for its 2019 growing season. In 2016, 2017 and 2018, the Company produced 41,000 lbs., 63,000 lbs. and 675,000 lbs., respectively, of dried hemp biomass.
[Editor's note: This story was previously published in March 2019. It has since been updated and republished.]Often, when analysts or bloggers talk up the potential of marijuana stocks, the focus is on the consumer side of the industry. But some of the best stocks in the pot sector may be medical marijuana stocks.Indeed, it's on the medical side where growth likely is to be largest in the near term. Canada did legalize recreational marijuana in October, but investors promptly sold the news in response. U.S. legalization is likely to be a long slog. Attitudes are mixed in Europe -- but even in legalized markets anywhere, black market (and untaxed) operators will be able to take share.InvestorPlace - Stock Market News, Stock Advice & Trading TipsMeanwhile, approval of medical marijuana (in the U.S. and elsewhere) seems to be moving at a faster pace. In such a highly regulated market, black market and even smaller producers likely will be shut out. Quality and consistency will be key. Here, scale will matter. And those companies that win early have the best chance of becoming market leaders -- and providing big gains for investors. * 10 Stocks to Buy That Wall Street Expects to Soar for the Rest of 2019 As always -- and particularly in this space -- investors need to mind the risks and size positions accordingly. But for investors who see medical marijuana stocks as the next big thing, these three are the best stocks to buy for investors enamored with weed.Source: Shutterstock Charlotte's Web (CWBHF)Charlotte's Web (OTCMKTS:CWBHF) has become one of the leading players in CBD oil (cannabidiol). And though Charlotte's Web products are made from hemp -- at least for now -- instead of marijuana, the stock still looks like one of the best plays in the sector.InvestorPlace's Matt McCall named CWBHF (the stock also trades on the Canadian Securities Exchange, ticker CWEB) as his pick for our list of the best stocks for 2019. And the case makes some sense. CBD oil sales are soaring, and Charlotte's Web is a market leader. As McCall pointed out, the federal farm bill in the U.S. provided a catalyst by legalizing hemp.With so many customers yet to try CBD oil -- and so many existing users attached -- market growth should be huge. And while CWBHF isn't cheap from a valuation standpoint, its position as a market leader should allow it to grow into its valuation.Source: Shutterstock Cronos (CRON)Of late, marijuana producer Cronos Group (NASDAQ:CRON) has made the headlines for its consumer business. Most recently, tobacco giant Altria (NYSE:MO) invested some $1.8 billion in the company. The combination of Altria's advertising and distribution reach and Cronos' production capabilities would seem to be the best fit for the consumer side of the business.But investors can't ignore that Cronos is a medical marijuana stock as well. In fact, it's that business that drives the majority of its revenue at the moment. And it also has given the company a beachhead in multiple markets around the world, from its home market of Canada to Germany, Israel and Poland. * 10 Stocks to Buy That Wall Street Expects to Soar for the Rest of 2019 I wrote after the Altria deal that investors should stay patient with CRON stock. And in this market, that might still be wise advice.Source: Shutterstock CannTrust (CTST)CannTrust (NYSE:CTST) has been one of the biggest victims of the post-legalization selloff. The stock lost more than half its value and touched a 52-week low in the process last year. And it's been in an almost continuous slump again since March.Unlike many peers, the company usually posts gross profits. And its established leadership in the Canadian medical marijuana industry should drive consistent growth and allow CannTrust to stay profitable. There is some retail exposure here as well, but unlike peers, CannTrust seems to have room to drive upside on the medical side alone.CannTrust also was able to get a listing on the New York Stock Exchange this year. Admittedly, uplisting hasn't helped pot stocks in and of itself (most notably Aurora Cannabis (NYSE:ACB) took a lot longer to take off than was expected), but it certainly didn't hurt.From a profitability standpoint, at least, CNNTF seems like one of the best stocks in the pot sector. And with valuation near the lows, at least some of the risks here likely are priced in.As of this writing, Vince Martin has no positions in any securities mentioned. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 10 Stocks to Buy That Wall Street Expects to Soar for the Rest of 2019 * 7 Value Stocks That Are Flying Under the Radar * 6 Mouth-Watering Fast Food Stocks for Growth Investors Compare Brokers The post 3 Medical Marijuana Stocks to Buy appeared first on InvestorPlace.
Shares of CBD company CV Sciences jumped 10% on a deal with retailer Kroger to sell its oils in nearly 1,000 stores.
June 2019 might hold some surprises for cannabis stocks. With the recent market downtrend, there are many great cannabis stocks potentially selling at a discount. It's become evident that cannabis is now consolidating and potentially setting up for the next wave of volatility. Whether that wave proves to be bullish or not is yet to be determined. For June 2019, there are a few stocks worth watching.Here is a short list of stocks to look out for June: Charlotte's Web Holdings (CWBHF)Charlotte’s Web, one of the leaders in hemp CBD extract products, is a new listing with incredible potential. It’s business model focuses mostly on hemp CBD products. Non-intoxicating and highly effective at improving health among many other uses, hemp is revolutionizing many industries. Charlotte’s Web is one of those companies leading the hemp revolution with CBD pet products, CBD capsules and extracts, and a wide range of other products. Although not considered technically ‘cannabis’, hemp has become an incredibly powerful movement in American agriculture.Hemp stocks in general are an interesting play. They offer a great alternative to purely cannabis stocks and give opportunity for investors in America to get into the cannabis market in some form. Hemp provides incredible value in the form of textiles, CBD, protein products, general nutrition (hemp seeds) and more. Charlotte’s Web is one of the companies leading the hemp revolution. So look out!In late April, Benchmark analyst Mike Hickey initiated coverage on Charlotte's Web's stock, with a Buy rating and a $25 price target, which is nearly 100% upside from current trading level.Hickey opined, "Our positive view on CWEB is based on the Company’s exposure to meaningful demand drivers that include: 1) Early leadership and brand development in the rapidly emerging domestic CBD market, which could reach $22B in 2022; 2) Recent passage of the 2018 Farm Bill where hemp is removed from the Controlled Substances Act and removed from the jurisdiction of the Drug Enforcement Agency (DEA); 3) A vertically integrated business model with a significant 2018 hemp harvest. CWEB has established manufacturing and distribution capabilities, all of which sets the stage for accelerating near term business growth; 4) Continued rapid expansion of CWEB’s product retail locations including national chains and growth from its ecommerce platform; 5) Ongoing brand development and product innovations that deliver CBD as the active ingredient. Anticipated new product offerings include consumables, pet offerings and differentiated topicals / cosmetics." Canopy Growth (CGC)Canopy Growth is also doing interesting things. Similar to Charlotte’s Web, it sees incredible potential in the current hemp market in the U.S.. It’s one of the first Canadian cannabis producers to enter the hemp CBD market and has large plans to expand that part of its business. Canopy is also highly invested in cannabis products such as edibles and beverages making is a very interesting company to look out for before Canada opens its doors to edibles later this year.GMP analyst Martin Landry recently reiterated a Buy rating on Canopy stock, with a C$72 price target, suggesting the stock can rise 30% from current levels.Landry noted, "The BC greenhouses appear to be running smoothly across all areas of production, trimming and drying. We value Canopy using a sum-of-the-parts with pro-forma share count assuming the Acreage acquisition closes. We value Acreage at 22x consensus 2021 EBITDA of US$292m for a value of $15.00 per pro-forma share. Our valuation of Canopy’s legacy operations is unchanged at $31b (or $56.00 using a pro-forma share count) and derived using a DCF calculation with the following: 1) a 7.5% discount rate, 2) a 28% share of the recreational market, (3) a 28% EBITDA margin, and (4) a 3.2% terminal growth."Overall, Canopy has had 7 bullish analysts in its corner over the last three months, and 4 analysts playing it safe on the sidelines. Importantly, the 12-month average price target of C$80.17 showcases 46% in upside potential for the stock. Namaste Technologies (NXTTF)Namaste stock is a love/hate relationship for many investors. It’s had a ‘journey’ of sorts trying to find its footing in the industry. Slowly consolidating after a bumpy ride from 3.74 in Oct 2018 to 0.88 for the last trading day of May 2019, it’s finally gaining a slight uptrend recently. Steadily trying to find its ground through all the adversity, Namaste may potentially be gearing back up to its former glory. June might see Namaste finally get its grip on the market.Bottom LineHemp stocks might have great potential in the next few months. Especially with the increasing social media hype and trade war. Canada itself is having issues with China and has had to cut exports of canola to China. Many farmers might start to replace those crops with hemp. So keep a look out for companies like Charlotte’s Web and Canopy. Tech might also start to rebound. Namaste has had a rough few months but is really well positioned in the cannabis space as a tech company and not a producer. Diversification is key and these three stocks provide different opportunities in the cannabis sector.To read more on the nitty gritty of what’s going on in the rising cannabis industry, click here.Disclosure: The author is Long NXTTF. Read more on the stocks mentioned: * Marijuana Stock Charlotte’s Web Looks Appealing at Current Levels * Cracks Are Forming in Canopy Growth (CGC) Stock * Namaste Technologies Stock Should Enjoy a Bright Future More recent articles from Smarter Analyst: * Organigram (OGI) Reported a Strong Quarter, But Don’t Buy the Stock Just Yet * More Gains Ahead for Cannabis Stock Curaleaf * Last Minute Thought: Buy or Sell Netflix (NFLX) Stock Before Q2’19 Earnings? * Is It Finally Time to Go Long NIO Stock? This Analyst Remains Sidelined
NEW YORK , June 4, 2019 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the launch of the OTCQX® Cannabis Index ...
BOULDER, CO , June 3, 2019 /CNW/ - Charlotte's Web Holdings, Inc. ("Charlotte's Web" or the "Company") (TSX:CWEB, OTCQX:CWBHF), the market leader in hemp CBD extract products, has officially unveiled its newest CBD product line - hemp extract-infused CBD Gummies – made with whole-plant extract from its prized hemp genetics and featuring synergistic functional ingredients to support specific health related functions including everyday stress, sleep, and recovery from exercise or active lifestyles. Available in a variety of flavors, gummies are the latest addition to the Company's expanding line of CBD hemp-extract products.
BOULDER, CO, May 31, 2019 /PRNewswire/ - Charlotte's Web Holdings, Inc. ("Charlotte's Web" or the "Company") (TSX:CWEB, OTCQX:CWBHF), the market leader in hemp CBD extract products, confirms commencement of trading of the Company's common shares (the "Common Shares") on the Toronto Stock Exchange (the "TSX") effective today, Friday May 31, 2019 under the stock ticker "CWEB". In conjunction with listing on the TSX, the Common Shares were voluntarily delisted from the Canadian Securities Exchange (the "CSE") as at the close of trading yesterday, Thursday, May 30, 2019.
Cannabis stocks fell Wednesday, weighed down by weakness in the broader markets and disappointment about some of the latest earnings from the sector.
Sales are soaring at this marijuana stock, but rising revenue isn't the only thing you should know about its performance last quarter.
Charlotte’s Web Holdings' Q1 Earnings: Key TakeawaysCharlotte’s Web HoldingsCharlotte’s Web Holdings (CWBHF) released its first-quarter earnings yesterday after the markets closed. The company reported revenues of $21.7 million in the quarter.